Medexus Reports Triamcinolone Hexacetonide Injectable Suspension Approved for Public Reimbursement in Canada
April 08 2020 - 8:30AM
Medexus Pharmaceuticals Inc. (the “Company” or
“Medexus”) (TSXV: MDP, OTCQB: PDDPF) is pleased to
announce that the pan-Canadian Pharmaceutical Alliance (pCPA) price
negotiations for Triamcinolone Hexacetonide Injectable Suspension
20mg/mL (TH) in Canada are completed with expected public
reimbursement to roll out in the respective provinces over the
coming months.
TH is the longest acting corticosteroid for
intra articular injection, often lasting twice as long as
competitive products. Health Canada previously approved TH in
December 2017 for intra-articular, intrasynovial, or periarticular
use in adults and adolescents for the symptomatic treatment of
subacute and chronic inflammatory joint diseases including:
rheumatoid arthritis, juvenile idiopathic arthritis (JIA),
osteoarthritis, post-traumatic arthritis, synovitis, tendinitis,
bursitis and epicondylitis.
As previously reported, there has been a
long-standing drug shortage of Triamcinolone Hexacetonide in
Canada. In October 2018, with the support of the Canadian
Rheumatology Association (CRA), the Company launched its own TH
product to help fill a care gap by bringing TH back to the market.
Since that time, the Company has provided TH to children with JIA
through the Special Access Program of Health Canada, providing
these children a reliable source for this product, which is a key
component for the management of their disease. Medexus’ commercial
launch of TH also allows the Company to promote its TH product for
use in adults for indications such as osteoarthritis, rheumatoid
arthritis and other forms of joint disease.
Ken d’Entremont, Chief Executive Officer of
Medexus, commented, “Public reimbursement marks an important
milestone for the Company, as it dramatically increases the sales
potential and market access to our TH product. Moreover,
children and adult patients suffering from debilitating forms of
joint disease now have a reliable source and greater access to
TH. Importantly, TH transforms the treatment of many severe
joint diseases as it provides a longer duration of action, with
fewer injections, compared to other corticosteroid injections and
intra-articular steroids. By reducing the number of injections, we
believe TH offers a safer and more cost-effective solution for the
healthcare system, by reducing the number of hospital visits and
need to put pediatric patients under general anesthetic for these
injections. Reducing the number of injections also helps
alleviate the time and stress burden on both parents and children.
Public reimbursement for TH is particularly important in the
current COVID-19 healthcare environment where patient visits to
hospitals should be reduced and focused on urgent patient needs. We
agree with the Canadian Rheumatology Association (CRA) in their
assessment that TH should be considered the standard of care, and
not only for younger patients with JIA, but for all appropriate
adult patients with subacute and chronic inflammatory joint
disease. Overall, we are quite encouraged by the response to TH
from the Canadian medical community and believe TH represents an
important market opportunity for Medexus going forward.”
About Medexus
Medexus is a leading specialty pharmaceutical
company with a strong North American commercial platform. The
Company’s vision is to provide the best healthcare products to
healthcare professionals and patients, through our core values of
Quality, Innovation, Customer Service and Teamwork. Medexus
Pharmaceuticals is focused on the therapeutic areas of auto-immune
disease, hematology and allergy. The Company’s leading products
are: Rasuvo™ and Metoject®, a unique formulation of methotrexate
(auto-pen and pre-filled syringe) designed to treat rheumatoid
arthritis and other auto-immune diseases; IXINITY®, an intravenous
recombinant factor IX therapeutic for use in patients 12 years of
age or older with Hemophilia B – a hereditary bleeding disorder
characterized by a deficiency of clotting factor IX in the blood,
which is necessary to control bleeding; and Rupall®, an innovative
allergy medication with a unique mode of action.
For more information, please
contact:
Ken d’Entremont, Chief Executive OfficerMedexus
Pharmaceuticals Inc.Tel.: 905-676-0003E-mail:
ken.dentremont@medexus.com
Roland Boivin, Chief Financial OfficerMedexus
Pharmaceuticals Inc.Tel.: 514-762-2626 ext. 202E-mail:
roland.boivin@medexus.com
Investor Relations
(U.S.):Crescendo Communications, LLCTel:
+1-212-671-1020Email: mdp@crescendo-ir.com
Investor Relations
(Canada):Frank CandidoDirect Financial Strategies and
Communication Inc.Tel: 514-969-5530E-mail:
frank.candido@medexusinc.com
Neither the TSX Venture Exchange nor its
Regulation Services Provider (as that term is defined in the
policies of the TSX Venture Exchange) accepts responsibility for
the adequacy or accuracy of this release.
READER ADVISORIES
Forward Looking Statements
Certain statements made in this press release
contain forward-looking information within the meaning of
applicable securities laws (“forward-looking
statements”). The words “anticipates”, “believes”,
“expects”, “will”, “plans” and similar expressions are often
intended to identify forward-looking statements, although not all
forward-looking statements contain these identifying words.
Specific forward-looking statements contained in this news release
include, but are not limited to, statements with respect to future
business operations, the timing of regulatory applications and
approvals and the efficacy and success of certain drug therapies.
These statements are based on factors or assumptions that were
applied in drawing a conclusion or making a forecast or projection,
including assumptions based on historical trends, current
conditions and expected future developments. Since forward-looking
statements relate to future events and conditions, by their very
nature they require making assumptions and involve inherent risks
and uncertainties. The Company cautions that although it is
believed that the assumptions are reasonable in the circumstances,
these risks and uncertainties give rise to the possibility that
actual results may differ materially from the expectations set out
in the forward-looking statements. Material risk factors include
those set out in the Company's most recent MD&A; future capital
requirements and dilution; intellectual property protection and
infringement risks; competition (including potential for generic
competition); reliance on key management personnel; the Company’s
ability to implement its business plan; the Company’s ability to
leverage its United States and Canadian infrastructure to promote
additional growth, including with respect to the infrastructure of
Medexus Inc. and Medac Pharma, Inc. and the potential benefits the
Company expects to derive therefrom;, regulatory approval by the
Canadian health authorities; product reimbursement by third party
payers; patent litigation or patent expiry; litigation risk; stock
price volatility; government regulation; and potential third party
claims. Given these risks, undue reliance should not be placed on
these forward-looking statements, which apply only as of the date
hereof. Other than as specifically required by law, the Company
undertakes no obligation to update any forward-looking statements
to reflect new information, subsequent or otherwise.
Medexus Pharmaceuticals (TSXV:MDP)
Historical Stock Chart
From Jun 2024 to Jul 2024
Medexus Pharmaceuticals (TSXV:MDP)
Historical Stock Chart
From Jul 2023 to Jul 2024